The University of Manchester

St Georges Hospital Medical School

St George's Hosptial Medical School

Clive Robinson

Trevor Robert Perrior

Mark Richard Stewart

Kerry Jenkins

Gary Karl Newton

Jihui Zhang

David Ronald Garrod

Meriel Ruth Major

Rebekah Elisabeth Key

Rebekah Elisabeth Beevers

David R Garrod

Meriel Ruth Mayor

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyruvamide compounds of the following formula (for convenience, collectively referred to herein as 'PVA compounds'), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy. 

Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use

The present invention pertains generally to the field of therapeutic compounds and more specifically to certain pyruvamide compounds of the formula (X) (for convenience, collectively referred to herein as 'PVA compounds'), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.

The present invention relates to the use of an inhibitor of cysteine proteinase activity in conjunction with an inhibitor of any serine proteinase activity other than trypsin for the manufacture of a medicament for the prevention or treatment of a condition in which an allergen traverses an epithelial barrier such as asthma. Also included in the invention are formulations and kits containing serine and cysteine proteinase inhibitors and their use in the prevention or treatment of conditions in which an allergen traverses an epithelial barrier.

Prevention and/or treatment of allergic conditions

Growing community of inventors

London, United Kingdom

Clive Robinson